Meeting
2019 Gastrointestinal Cancers Symposium
Dose escalation and expansion cohort study for DS-8895a in patients with advanced solid tumors.
Authors
Taroh Satoh
Department of Frontier Science for Cancer and Chemotherapy Osaka University Graduate School of Medicine, Osaka, Japan
Taroh Satoh , Kohei Shitara , Satoru Iwasa , Kensei Yamaguchi , Kei Muro , Yoshito Komatsu , Tomohiro Nishina , Taito Esaki , Jun Hasegawa , Yasuyuki Kakurai , Emi Kamiyama , Tomoko Nakata , Kota Nakamura , Ichinosuke Hyodo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02004717
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 99)
DOI
10.1200/JCO.2019.37.4_suppl.99
Abstract #
99
Poster Bd #
J9
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: Preliminary safety and pharmacokinetic (PK)/pharmacodynamic results.
First Author: Omid Hamid
Poster
2015 ASCO Annual Meeting
First-in-human dose escalation, safety, and PK study of a novel EFNA4-ADC in patients with advanced solid tumors.
First Author: David S. Hong
Poster
2015 ASCO Annual Meeting
Phase I study of the safety and tolerability of the Exportin 1 (XPO1) inhibitor Selinexor (SXR) in Asian patients (pts) with advanced solid cancers.
First Author: David Shao Peng Tan
Poster
2024 ASCO Annual Meeting
Preliminary results of a phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors.
First Author: Roger J. Waltzman